MedTrace Logo

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

NCT05491694 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-08-08

No results posted yet for this study

Summary

To investigate the efficacy and safety of terbinumab combined with chemotherapy (epirubicin + cyclophosphamide → nab-paclitaxel + carboplatin) in neoadjuvant therapy of triple-negative breast cancer after HIFU.

Conditions

Interventions

DRUG

Toripalimab

Toripalimab 240mg

DRUG

Epirubicin

90mg/m2，IVD，q3w

PROCEDURE

High Intensity Focused Ultrasoun

HIFU treatment at lesion site

DRUG

Cyclophosphamide

600mg/m2，IVD，q3w

DRUG

Carboplatin

AUC 5，IVD，q3w

DRUG

Nab-paclitaxel

260mg/m2，IVD，q3w

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-12-30
Completion
2024-12-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491694 on ClinicalTrials.gov